HS-10390
/ Jiangsu Hansoh Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 29, 2026
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
(clinicaltrials.gov)
- P2 | N=182 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
New P2 trial • Chronic Kidney Disease • Nephrology • Renal Disease
October 10, 2024
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
(clinicaltrials.gov)
- P2 | N=90 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company
New P2 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
October 09, 2024
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=84 | Recruiting | Sponsor: Hansoh BioMedical R&D Company | Trial completion date: Feb 2024 ➔ Dec 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024
Trial completion date • Trial primary completion date • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Renal Disease
July 12, 2023
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=84 | Recruiting | Sponsor: Hansoh BioMedical R&D Company
New P1 trial • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Renal Disease
1 to 4
Of
4
Go to page
1